CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Although CD34 CML cells respond to MPA mainly by apoptosis, it may be a powerful tool in the evolved CML disease or TKI resistant like those harbouring the T315I mutation or overexpressing tyrosine kinases.